Trial Profile
A Randomized, Blinded Placebo-Controlled Study to Evaluate the Effect of Repeat Oral Doses of Pazopanib (GW786034) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Subjects With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Moxifloxacin
- Indications Bacterial infections; Solid tumours
- Focus Pharmacodynamics
- 06 Apr 2010 Actual patient number (96) added, actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 06 Apr 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.